Top

Published in:

01-08-2017 | Literatur kommentiert

Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv

Author: Prof. Dr. med. Stephan Roth

Published in: Strahlentherapie und Onkologie | Issue 8/2017

Auszug

Nach einer radikalen Prostatektomie wegen eines lokal begrenzten Prostatakarzinoms steigt in ca. 30 % der Fälle der PSA-Wert als Hinweis auf ein Rezidiv. Nach einer Salvage-Strahlentherapie kommt es in bis zu 50 % der Fälle zu einem Rezidiv. Deshalb ist es von Interesse, ob bei einem Prostatakarzinomrezidiv Antiandrogene zusätzlich zur Bestrahlung gegeben werden sollten [1, 3]. …

Abdollah F, Karnes RJ, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947CrossRefPubMed

Adam M, Tennstedt P, Lanwehr D, DeryaTilki D (2017) Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy. Eur Urol 71:330–336CrossRefPubMed

AWMF-Register-Nummer 043/022OL.(2014) Interdisziplinäre Leitlinie der QualitätS3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Kurzversion 3.1.

Buscariollo DL, Drumm M, Niemierko A et al (2017) Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol 7(2):e125–e133CrossRefPubMed

Bolla M, van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10 year results of an EORTC randomized study. Lancet Oncol 11:1066–1073CrossRefPubMed

Briganti A, Wiegel T, Joniau S et al (2012) Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 62(3):472–487. doi:10.1016/j.eururo.2012.04.056

Carrie C, Hasbini A, de Laroche G et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy(GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747–756CrossRefPubMed

Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642CrossRefPubMed

Gandaglia G, Briganti A, Clarke N (2017) Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol 17:30064–30067

10.

Goenka A, Magsanoc JM, Pei X, Schechter M et al (2012) Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84(1):112–118CrossRefPubMed

11.

Iversen P, Tyrrell CJ, Kaisary AV et al. (1988) Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51(3):389–396

12.

Mottet N, Peneau M, Mazeron JJ et al (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62(2):213–219

13.

Ost P, De Troyer B, Fonteyne V et al (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80(5):1316–1322

14.

Schüler HG, Guckenberger M (2017) LITERATUR KOMMENTIERT: Kein Nachweis einer Ergebnisverbesserung der Salvage-Radiotherapie beim asymptomatischen biochemischen Prostatakarzinomrezidiv mach Prostatektomie durch additive Androgensuppression. Strahlenther Onkol 193:86–88CrossRef

15.

Shipley WU, Seiferheld W, Lukka HR (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428CrossRefPubMed

16.

Soto DE, Passarelli MN, Daignault S, Sandler HM (2012) Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 82:112–118CrossRef

17.

Pilepich MV, Caplan R, Byhardt RW et al (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15(3):1013–1021

18.

Stish BJ, Pisansky TM, Harmsen WS (2016) Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. Clin Oncol 34(32):3864–3871. doi:10.1200/JCO.2016.68.3425

19.

Tilki D, Preisser F, Tennstedt P (2016) Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int. doi:10.1111/bju.13679

20.

Wiegel T, Lohm G, Bottke D et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome-results of a retrospective study. Int J Radiat Oncol Biol Phys 73:1009–1016CrossRefPubMed

21.

Wirth MP, Weissbach L, Marx FJ et al (2004) Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45(3):267–270

Title: Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv
Author: Prof. Dr. med. Stephan Roth
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 8/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1171-4

ACC 2024 Congress

Springer Medicine

Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv

Auszug

ACC 2024 Congress

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 8/2017

Successful treatment of a rare case of ameloblastic fibrosarcoma with radiation therapy

Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy

Personalized radiotherapy for invasive breast cancer in 2017

Quantitative Risikoabschätzung einer Herzinsuffizienz bei Patienten mit Hodgkin-Lymphom nach Strahlentherapie und anthrazyklinhaltiger Chemotherapie

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer

Erratum to: Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters